The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Delta Air Lines and Bristol-Myers Squibb stocks are currently trading at discounts to their estimated fair values amid new operational catalysts. Bristol-Myers recently received EU approval for Opdivo, while Delta announced a $1 billion investment to retrofit its Airbus fleet starting in 2027. Despite carrying only 18% of passengers, Delta captures half of all U.S. airline profits, supported by customers paying a 20% premium for its reliable service.